Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08-13

AUTHORS

John Ascher, Annette Stemhagen, Monika Stender, Beta Win, Christina Winter

ABSTRACT

BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban. OBJECTIVE: Assess participants' understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides. METHODS: A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for ≥ 80% of participants to respond correctly to each question regarding neuropsychiatric risks. RESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time. CONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation. More... »

PAGES

181-191

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0140-2

DOI

http://dx.doi.org/10.1007/s40801-018-0140-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106123175

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30105744


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Classic and Established Medicines, US Medical Affairs, GSK, Research Triangle Park, NC USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Classic and Established Medicines, US Medical Affairs, GSK, Research Triangle Park, NC USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ascher", 
        "givenName": "John", 
        "id": "sg:person.01153032071.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153032071.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Safety, Epidemiology and Risk Management, UBC, Blue Bell, PA USA", 
          "id": "http://www.grid.ac/institutes/grid.456262.1", 
          "name": [
            "Safety, Epidemiology and Risk Management, UBC, Blue Bell, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stemhagen", 
        "givenName": "Annette", 
        "id": "sg:person.014331720131.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014331720131.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Real World Evidence and Epidemiology, GSK, Stockley Park, Uxbridge, Middlesex UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Real World Evidence and Epidemiology, GSK, Stockley Park, Uxbridge, Middlesex UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stender", 
        "givenName": "Monika", 
        "id": "sg:person.01131521505.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131521505.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Clinical Safety and Pharmacovigilance, GSK, Stockley Park, Uxbridge, Middlesex UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Global Clinical Safety and Pharmacovigilance, GSK, Stockley Park, Uxbridge, Middlesex UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Win", 
        "givenName": "Beta", 
        "id": "sg:person.013737250145.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013737250145.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Clinical Safety and Pharmacovigilance, GSK, Stockley Park, Uxbridge, Middlesex UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Global Clinical Safety and Pharmacovigilance, GSK, Stockley Park, Uxbridge, Middlesex UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winter", 
        "givenName": "Christina", 
        "id": "sg:person.011444171713.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011444171713.08"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40801-015-0042-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018259015", 
          "https://doi.org/10.1007/s40801-015-0042-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1177/2168479014524407", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023848401", 
          "https://doi.org/10.1177/2168479014524407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200831110-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050731222", 
          "https://doi.org/10.2165/00002018-200831110-00006"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08-13", 
    "datePublishedReg": "2018-08-13", 
    "description": "BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban.\nOBJECTIVE: Assess participants' understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides.\nMETHODS: A cross-sectional study was conducted among patients\u2009\u2265\u200918\u00a0years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6\u00a0months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for\u2009\u2265\u200980% of participants to respond correctly to each question regarding neuropsychiatric risks.\nRESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time.\nCONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0140-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "smoking cessation", 
      "medication guide", 
      "neuropsychiatric risks", 
      "bupropion hydrochloride", 
      "neuropsychiatric adverse events", 
      "healthcare provider referrals", 
      "cross-sectional study", 
      "years of age", 
      "adverse events", 
      "provider referral", 
      "patient knowledge", 
      "patient understanding", 
      "cessation", 
      "pharmacy network", 
      "survey invitation", 
      "risk", 
      "Risk Associated", 
      "Behavior Survey", 
      "three-quarters", 
      "participants", 
      "prescription", 
      "risk questions", 
      "Zyban", 
      "participants' understanding", 
      "patients", 
      "risk evaluation", 
      "referral", 
      "hydrochloride", 
      "months", 
      "online panel", 
      "effective aid", 
      "age", 
      "survey", 
      "Associated", 
      "study", 
      "better understanding", 
      "years", 
      "use", 
      "guide", 
      "assessment", 
      "half", 
      "evaluation", 
      "understanding", 
      "events", 
      "panel", 
      "strategy assessment", 
      "questions", 
      "invitation", 
      "knowledge", 
      "attitudes", 
      "time", 
      "products", 
      "results", 
      "aid", 
      "part", 
      "network", 
      "Year 7 Risk Evaluation", 
      "Mitigation Strategy (REMS) assessment", 
      "Assess participants' understanding", 
      "bupropion hydrochloride products", 
      "hydrochloride products", 
      "neuropsychiatric risk questions", 
      "Year 7 REMS survey", 
      "REMS survey", 
      "Neuropsychiatric Risks Associated"
    ], 
    "name": "Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation", 
    "pagination": "181-191", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106123175"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0140-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30105744"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0140-2", 
      "https://app.dimensions.ai/details/publication/pub.1106123175"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_771.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0140-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0140-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0140-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0140-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0140-2'


 

This table displays all metadata directly associated to this object as RDF triples.

174 TRIPLES      22 PREDICATES      94 URIs      83 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0140-2 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N31bbee26d0d84a64bf3c7fa001053316
4 schema:citation sg:pub.10.1007/s40801-015-0042-5
5 sg:pub.10.1177/2168479014524407
6 sg:pub.10.2165/00002018-200831110-00006
7 schema:datePublished 2018-08-13
8 schema:datePublishedReg 2018-08-13
9 schema:description BACKGROUND: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban. OBJECTIVE: Assess participants' understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides. METHODS: A cross-sectional study was conducted among patients ≥ 18 years of age, who had used or filled a prescription for branded bupropion hydrochloride for smoking cessation in the past 6 months. Participants were recruited through an online panel, pharmacy network, or by healthcare provider referral, and invited to complete a survey containing questions regarding the risks associated with the use of branded bupropion hydrochloride products, and whether they had received and read the Medication Guide. The study aimed for ≥ 80% of participants to respond correctly to each question regarding neuropsychiatric risks. RESULTS: From the 50,985 survey invitations distributed, 1017 participants responded, of whom 144 were eligible and 142 completed the survey. Over 80% of participants correctly responded to most neuropsychiatric risk questions. Approximately three-quarters of participants received the Medication Guide when they last filled their prescription, of whom over half read the Medication Guide at that time. CONCLUSIONS: Participants enrolled in this Year 7 REMS survey had good understanding of the neuropsychiatric risks associated with using branded bupropion hydrochloride products for smoking cessation.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N8c1cfd69c806448dad2ca6ab6b8a5a03
14 Ndcc3ecdfa41c4f97bd14fe317d3af615
15 sg:journal.1051855
16 schema:keywords Assess participants' understanding
17 Associated
18 Behavior Survey
19 Mitigation Strategy (REMS) assessment
20 Neuropsychiatric Risks Associated
21 REMS survey
22 Risk Associated
23 Year 7 REMS survey
24 Year 7 Risk Evaluation
25 Zyban
26 adverse events
27 age
28 aid
29 assessment
30 attitudes
31 better understanding
32 bupropion hydrochloride
33 bupropion hydrochloride products
34 cessation
35 cross-sectional study
36 effective aid
37 evaluation
38 events
39 guide
40 half
41 healthcare provider referrals
42 hydrochloride
43 hydrochloride products
44 invitation
45 knowledge
46 medication guide
47 months
48 network
49 neuropsychiatric adverse events
50 neuropsychiatric risk questions
51 neuropsychiatric risks
52 online panel
53 panel
54 part
55 participants
56 participants' understanding
57 patient knowledge
58 patient understanding
59 patients
60 pharmacy network
61 prescription
62 products
63 provider referral
64 questions
65 referral
66 results
67 risk
68 risk evaluation
69 risk questions
70 smoking cessation
71 strategy assessment
72 study
73 survey
74 survey invitation
75 three-quarters
76 time
77 understanding
78 use
79 years
80 years of age
81 schema:name Patient Understanding of the Neuropsychiatric Risks Associated with Branded Bupropion Hydrochloride Products Used for Smoking Cessation
82 schema:pagination 181-191
83 schema:productId N9428a2d975f84c6b82430279b5829c92
84 Nb8124bf44d1843cc8fea94424202042e
85 Ncbf262241af041fbb3effe5c34a72747
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106123175
87 https://doi.org/10.1007/s40801-018-0140-2
88 schema:sdDatePublished 2021-12-01T19:40
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher N47021c05dfc6405bad6d1df972ebd9f8
91 schema:url https://doi.org/10.1007/s40801-018-0140-2
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N2ef0df66da1c4744b9f9bd23b08747d4 rdf:first sg:person.013737250145.19
96 rdf:rest N36d1ab6358064fc7b5e92566ca78276a
97 N31bbee26d0d84a64bf3c7fa001053316 rdf:first sg:person.01153032071.17
98 rdf:rest Ndedc7192cae649d988f13599c0368498
99 N36d1ab6358064fc7b5e92566ca78276a rdf:first sg:person.011444171713.08
100 rdf:rest rdf:nil
101 N47021c05dfc6405bad6d1df972ebd9f8 schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 N573b8e8f86104824b8b54a13c9fafa3e rdf:first sg:person.01131521505.39
104 rdf:rest N2ef0df66da1c4744b9f9bd23b08747d4
105 N8c1cfd69c806448dad2ca6ab6b8a5a03 schema:volumeNumber 5
106 rdf:type schema:PublicationVolume
107 N9428a2d975f84c6b82430279b5829c92 schema:name doi
108 schema:value 10.1007/s40801-018-0140-2
109 rdf:type schema:PropertyValue
110 Nb8124bf44d1843cc8fea94424202042e schema:name pubmed_id
111 schema:value 30105744
112 rdf:type schema:PropertyValue
113 Ncbf262241af041fbb3effe5c34a72747 schema:name dimensions_id
114 schema:value pub.1106123175
115 rdf:type schema:PropertyValue
116 Ndcc3ecdfa41c4f97bd14fe317d3af615 schema:issueNumber 3
117 rdf:type schema:PublicationIssue
118 Ndedc7192cae649d988f13599c0368498 rdf:first sg:person.014331720131.05
119 rdf:rest N573b8e8f86104824b8b54a13c9fafa3e
120 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
121 schema:name Medical and Health Sciences
122 rdf:type schema:DefinedTerm
123 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
124 schema:name Public Health and Health Services
125 rdf:type schema:DefinedTerm
126 sg:journal.1051855 schema:issn 2198-9788
127 2199-1154
128 schema:name Drugs - Real World Outcomes
129 schema:publisher Springer Nature
130 rdf:type schema:Periodical
131 sg:person.01131521505.39 schema:affiliation grid-institutes:None
132 schema:familyName Stender
133 schema:givenName Monika
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131521505.39
135 rdf:type schema:Person
136 sg:person.011444171713.08 schema:affiliation grid-institutes:None
137 schema:familyName Winter
138 schema:givenName Christina
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011444171713.08
140 rdf:type schema:Person
141 sg:person.01153032071.17 schema:affiliation grid-institutes:None
142 schema:familyName Ascher
143 schema:givenName John
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153032071.17
145 rdf:type schema:Person
146 sg:person.013737250145.19 schema:affiliation grid-institutes:None
147 schema:familyName Win
148 schema:givenName Beta
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013737250145.19
150 rdf:type schema:Person
151 sg:person.014331720131.05 schema:affiliation grid-institutes:grid.456262.1
152 schema:familyName Stemhagen
153 schema:givenName Annette
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014331720131.05
155 rdf:type schema:Person
156 sg:pub.10.1007/s40801-015-0042-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018259015
157 https://doi.org/10.1007/s40801-015-0042-5
158 rdf:type schema:CreativeWork
159 sg:pub.10.1177/2168479014524407 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023848401
160 https://doi.org/10.1177/2168479014524407
161 rdf:type schema:CreativeWork
162 sg:pub.10.2165/00002018-200831110-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050731222
163 https://doi.org/10.2165/00002018-200831110-00006
164 rdf:type schema:CreativeWork
165 grid-institutes:None schema:alternateName Classic and Established Medicines, US Medical Affairs, GSK, Research Triangle Park, NC USA
166 Global Clinical Safety and Pharmacovigilance, GSK, Stockley Park, Uxbridge, Middlesex UK
167 Real World Evidence and Epidemiology, GSK, Stockley Park, Uxbridge, Middlesex UK
168 schema:name Classic and Established Medicines, US Medical Affairs, GSK, Research Triangle Park, NC USA
169 Global Clinical Safety and Pharmacovigilance, GSK, Stockley Park, Uxbridge, Middlesex UK
170 Real World Evidence and Epidemiology, GSK, Stockley Park, Uxbridge, Middlesex UK
171 rdf:type schema:Organization
172 grid-institutes:grid.456262.1 schema:alternateName Safety, Epidemiology and Risk Management, UBC, Blue Bell, PA USA
173 schema:name Safety, Epidemiology and Risk Management, UBC, Blue Bell, PA USA
174 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...